Basics Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company develops novel adult stem cell therapies for debilitating neurodegenerative disorders such as ALS, MS, and PD among others. IPO Date: November 1, 2003 Sector: Healthcare Industry: Biotech Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 3.47% Avg Daily Range (30 D): $0.03 | 4.09% Avg Daily Range (90 D): $0.04 | 4.47% Institutional Daily Volume Avg Daily Volume: .36M Avg Daily Volume (30 D): .03M Avg Daily Volume (90 D): .73M Trade Size Avg Trade Size (Sh.): 256 Avg Trade Size (Sh.) (30 D): 672 Avg Trade Size (Sh.) (90 D): 184 Institutional Trades Total Inst.Trades: 43 Avg Inst. Trade: $2.23M Avg Inst. Trade (30 D): $.62M Avg Inst. Trade (90 D): $.62M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.72M Avg Closing Trade (30 D): $M Avg Closing Trade (90 D): $M Avg Closing Volume: 29.88K     News Aug 14, 2025 @ 11:02 AM BrainStorm Cell Therapeutics Announces Second Quar... Source: Prnewswire Jul 18, 2025 @ 9:36 AM Brainstorm Cell Therapeutics Crashes 42% After Vol... Source: Mohd Haider May 6, 2025 @ 11:00 AM BrainStorm to Present Biomarker Insights Supportin... Source: Prnewswire Mar 26, 2025 @ 12:15 PM BrainStorm Cell Therapeutics Granted Compliance Ex... Source: Prnewswire Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.34 $-.45 $-.51 Diluted EPS $-.34 $-.45 $-.51 Revenue $ $ $ Gross Profit $ $ $ Net Income / Loss $ -2.9M $ -2.86M $ -2.97M Operating Income / Loss $ -2.57M $ -3.09M $ -3.19M Cost of Revenue $ $ $ Net Cash Flow $ M $ M $ -1.11M PE Ratio     Splits Oct 01, 2024:   1:15 Sep 16, 2014:   1:15 Aug 13, 2003:   2:1